Page 1

Exhibit 99.1 immunome Immunome Reports First Quarter 2021 Financial Results -IMM - BCP - 01 : Selected antibody cocktail demonstrating neutralization of CDC SARS - CoV - 2 " variants of concern " in preclinical testing , progressing towards IND filing - -IMM - ONC - 01 : Advanced proprietary antibody against IL - 38 , a novel innate immune checkpoint , into IND - enabling studies - - Dennis Giesing , Ph.D. appointed as Chief Development Officer and Corleen Roche appointed as Chief Financial Officer - - Raised $ 27 million in gross proceeds in a private placement - Exton , Pa . , May 12 , 2021 - Immunome , Inc. ( Nasdaq : IMNM ) , a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first - in - class antibody therapeutics , today reported financial results for the first quarter ended March 31 , 2021 and provided a corporate update . First Quarter and Subsequent Highlights • • IMM - BCP - 001 : In February 2021 , Immunome announced that it discovered antibodies capable of neutralizing multiple SARS - CoV - 2 variants , including the South African Variant , in pseudovirus testing . In April 2021 , the company announced antibody selection for its IMM - BCP - 01 cocktail and shared data showing that IMM - BCP - 01 neutralizes CDC SARS - CoV - 2 " Variants of Concern " in preclinical testing . The cocktail was efficacious in Syrian hamsters infected with SARS - CoV - 2 ( USA - WA 1/2020 ) in both prophylactic and treatment schedules . Further , the cocktail neutralized South Africa and UK variants in live virus testing and Brazil and California variants in pseudovirus testing . An Investigational New Drug ( IND ) filing for IMM - BCP - 001 is planned for late 2Q / early 3Q 2021 . IMM - ONC - 001 : In March 2021 , Immunome announced its proprietary antibody against IL - 38 advanced into IND - enabling studies . Based on Immunome's research findings , IL - 38 functions as a novel innate immune checkpoint that inhibits infiltration and pro - inflammatory activity of innate immune cells . The company's analysis also suggests that IL - 38 is over - expressed in certain tumors and is potentially linked to reduced infiltration of innate immune cells . Immunome anticipates filing an IND for this product candidate in 2H 2021 . • • Appointed Dr. Dennis Giesing as Chief Development Officer and Corleen Roche as Chief Financial Officer . In March 2021 , the company announced the appointment of Dennis Giesing , Ph.D. to the role of Chief Development Officer . Dr. Giesing brings more than 35 years of pharmaceutical industry experience to Immunome and will be responsible for driving Immunome's programs into clinical development . In April 2021 , Immunome announced that it appointed Corleen Roche as its Chief Financial Officer . Ms. Roche is a highly accomplished CFO with over 30 years of industry experience to lead the company's finance and corporate strategy functions . Completed a $ 27 million private placement . In April 2021 , the company announced a private placement of its common stock for gross proceeds to Immunome of approximately $ 27 million , before deducting placement agent commissions and other offering expenses . The company currently expects the proceeds from this private placement , together with its cash on hand , will be sufficient to fund its operations through fiscal year 2022 . “ I am thrilled with the significant progress that Immunome has made in the development of our product pipeline , ” said Purnanand Sarma , Ph.D. , President and CEO of Immunome . " We are excited to welcome Dr. Giesing and Ms. Roche to the Immunome team as we move towards becoming a clinical stage biopharmaceutical company . " Financial Highlights • Research and development ( R & D ) expenses : R & D expenses for the three months ended March 31 , 2021 were $ 2.0 million . • General and administrative ( G & A ) expenses : G & A expenses for the three months ended March 31 , 2021 were $ 1.9 million . • • Net loss : Net loss for the three months ended 2021 was $ 3.9 million . Cash and cash equivalents : As of March 31 , 2021 , cash and cash equivalents totaled $ 36.3 million ( excluding $ 27.0 million in proceeds from the private placement in April 2021 ) . About Immunome Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first - in - class antibody therapeutics that are designed to change the way diseases are treated . The company's initial focus is on developing therapeutics to treat oncology and infectious diseases , including COVID - 19 . Immunome's proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system , memory B cells , from patients whose bodies have learned to fight off their disease . For more information , please visit www.immunome.com . Forward - Looking Statements This press release includes certain disclosures that contain " forward - looking statements " intended to qualify for the “ safe harbor ” from liability established by the Private Securities Litigation Reform Act of 1995 , as amended , including , without limitation , express or implied statements regarding Immunome's beliefs and expectations regarding the advancement of its oncology and COVID - 19 therapeutic antibody programs , execution of its clinical and strategic plans , anticipated upcoming milestones for IMM - BCP - 01 and IMM - ONC - 01 , including expectations regarding therapeutic potential and benefits thereof , and IND filings . Forward - looking statements may be identified by the words " anticipate , " believe , ” “ estimate , ” “ expect , ” “ intend , ” “ plan , ” “ project , ” “ may , ” “ will , ” “ could , ” “ should , ” “ seek , ” “ potential ” and similar expressions . Forward - looking statements are based on Immunome's current expectations and are subject to inherent uncertainties , risks and assumptions that are difficult to predict . Factors that could cause actual results